Literature DB >> 1617072

Streptococcal and enterococcal bacteremia in patients with cancer.

A Awada1, P van der Auwera, F Meunier, D Daneau, J Klastersky.   

Abstract

Eighty-two episodes of bacteremia due to streptococci (including the genus Enterococcus) in 78 patients hospitalized at Institut Jules Bordet between 1986 and 1988 were reviewed. The incidence ranged from 5.5 to 7.6 per 1,000 admissions (16% of all bacteremias). Enterococcus faecalis, Streptococcus sanguis, and Streptococcus mitis were the most prevalent isolates, followed by Streptococcus angionosus, Streptococcus salivarius, and large colony-forming beta-hemolytic species (A, B, C, and G). Twenty-one episodes were polymicrobial. One-half of the patients had solid tumors, and one-half had hematologic malignancies. Forty-two patients were neutropenic (less than 1,000 polymorphonuclear neutrophils/microL). Only 15 episodes were acquired outside the hospital, and 11 episodes were breakthrough bacteremias. Twenty patients died within 1 month of the onset of streptococcal bacteremia. Five patients, two of whom were neutropenic, had fatal adult respiratory distress syndrome. The source of bacteremia remained undetermined in 35.4% of the episodes; the oral mucous membrane and the gastrointestinal tract were the most frequently recognized associated sites of infection. No unexpected antimicrobial resistance was observed except in two penicillin-resistant strains, one S. mitis and one E. faecium. No relation between peak or trough serum bactericidal titers and outcome could be demonstrated.

Entities:  

Mesh:

Year:  1992        PMID: 1617072     DOI: 10.1093/clinids/15.1.33

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  38 in total

1.  Susceptibilities of oral and nasal isolates of Streptococcus mitis and Streptococcus oralis to macrolides and PCR detection of resistance genes.

Authors:  T Ono; S Shiota; K Hirota; K Nemoto; T Tsuchiya; Y Miyake
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

2.  Meningitis due to Streptococcus salivarius.

Authors:  P Idigoras; A Valiente; L Iglesias; P Trieu-Cout; C Poyart
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

3.  All detectable high-molecular-mass penicillin-binding proteins are modified in a high-level beta-lactam-resistant clinical isolate of Streptococcus mitis.

Authors:  A Amoroso; D Demares; M Mollerach; G Gutkind; J Coyette
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

4.  Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae.

Authors:  Luz Balsalobre; María José Ferrándiz; Josefina Liñares; Fe Tubau; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

5.  Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.

Authors:  A Saleh-Mghir; A Lefort; Y Petegnief; S Dautrey; J M Vallois; D Le Guludec; C Carbon; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

6.  E test versus agar dilution for antimicrobial susceptibility testing of viridans group streptococci.

Authors:  S J Rosser; M J Alfa; S Hoban; J Kennedy; G K Harding
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

7.  Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants.

Authors:  M Hidalgo; J Hornedo; C Lumbreras; J M Trigo; C Gómez; S Perea; A Ruiz; R Hitt; H Cortés-Funes
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 8.  Use of the quinolones in the prophylaxis and treatment of granulocytopenic immunocompromised cancer patients.

Authors:  P Van der Auwera; J Gérain
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  A prospective, randomized study of pefloxacin versus teicoplanin in the treatment of gram-positive coccal infections in cancer patients: early termination due to emergence of resistance to fluoroquinolones.

Authors:  M Aoun; P Van der Auwera; I Varthalitis; A M Bourguignon; M Janssen; D Daneau; F Meunier
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

10.  A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis.

Authors:  W V Kern; B Hay; P Kern; R Marre; R Arnold
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.